Parallel Health World News Logo
update

Parallel Health World

cropper
update
  • Home
  • Categories
    • EcoHealth Trends
    • Healing Naturally
    • Age-Defying Diets
    • Supplement Savvy
    • Mind-Body Synergy
    • Finance and Health
    • Biolimitless
    • Tech Hacks
    • Health & Medicine
    • Political
    • BioBuzz
    • Holistic Rehabilitation Techniques
    • Practitioner Insights
    • AI In Healthcare
  • Featured Business Profiles
March 23.2026
3 Minutes Read

PH-762 Shows Promise as a New PD-1 Immunotherapy for Skin Cancer

PD-1 Immunotherapy concept for skin cancer with molecular structures.

The Cutting Edge of Immunotherapy: PH-762's Promising Results

Phio Pharmaceuticals is making headlines in the medical community as it gears up for a significant presentation on March 28, 2026, at the American Academy of Dermatology's Late-Breaking Research Session. The company will unveil results from their Phase 1b clinical study of PH-762, a novel treatment for cutaneous carcinomas, including melanoma and squamous cell carcinoma. This research underscores the potential of immunotherapy in the fight against skin cancer, aiming to transform how patients receive treatment.

Immunotherapy, particularly PD-1 directed treatments, have revolutionized oncology. Unlike traditional therapies that may involve broad systemic effects and off-target toxicity, PH-762 utilizes a self-delivering RNA interference technology called INTASYL®, designed to silence the PD-1 mRNA in immune cells, thereby enhancing the body’s ability to combat tumor cells. This method minimizes adverse effects typically associated with immunotherapies, leading to a more targeted intervention.

Exciting Study Results That Signal Hope

Preliminary data from the ongoing clinical trial indicates that PH-762 is well tolerated among patients. Notably, the therapy has shown an encouraging 65% pathologic response rate in cutaneous squamous cell carcinoma across all dosing cohorts, with the highest-dose cohort exhibiting an impressive 85% response rate. These findings are pivotal as they hint at a new, potentially non-surgical treatment option for patients battling aggressive forms of skin cancer.

In the latest update from Phio Pharmaceuticals, 22 patients have completed treatment without significant adverse effects, which is a promising sign for future clinical applications. The company has scheduled discussions with the FDA regarding the therapy's next stages of development, further paving the path for regulatory approval.

The Future of Oncology Treatment: Why This Matters

The implications of Phio Pharmaceuticals’ advancements extend beyond the specifics of the study. With rising skin cancer rates globally, there is an urgent need for effective treatments that offer patients hope without compromising their quality of life. The approach of utilizing local immunotherapy rather than systemic treatments could reshape patient experiences and outcomes significantly.

The medical community’s increasing reliance on targeted therapies, like PH-762, is indicative of a broader trend within oncology—an emphasis on personalized medicine tailored to the genetic and molecular profiles of individual tumors. As healthcare providers and patients alike become more informed about the potential of such innovations, the demand for tailored therapeutics will only continue to grow.

What’s Next for PH-762 and the Immunotherapy Landscape?

As Phio positions itself at the forefront of this transformative moment in cancer treatment, it raises important questions about the future of immunotherapy. How will regulatory bodies respond to emerging data? Will other companies follow suit with their innovations in local immunotherapy treatments? These developments will likely define the next generation of cancer therapies.

Phio's journey with PH-762 exemplifies the exciting advancements underway in immuno-oncology. With their focus on enhancing the body’s immune response precisely where it's needed, PH-762 not only shows the potential to treat existing tumors but could also reduce recurrence rates, which is a vital component of long-term cancer control.

Join the Conversation

As the medical community and the public await the presentation on PH-762, it is imperative to stay informed about ongoing developments in this field. Engaging in discussions around new treatments and fostering awareness can drive further innovation and patient support. Anyone interested in the latest trends in skin cancer treatment should keep a close eye on Phio Pharmaceuticals’ progress.

Health & Medicine

0 Views

0 Comments

Write A Comment

*
*
Please complete the captcha to submit your comment.
Related Posts All Posts
05.09.2026

Iraq Slashes Oil Prices Amid Geopolitical Tensions: What It Means for the Global Market

Update Understanding Iraq’s Bold Oil Price Cuts In a striking move, Iraq has slashed oil prices significantly, offering discounts of up to $33.40 per barrel for its Basrah Medium crude for May shipments. This decision is primarily aimed at attracting buyers who are wary of the escalating instability in the Strait of Hormuz, a critical channel for global oil transport. Amid heightened geopolitical tensions, Baghdad is recognizing the urgency to maintain its status as a top oil exporter by incentivizing trade with substantial price cuts. Geopolitical Tensions and Oil Supply Risks The Strait of Hormuz has increasingly become a focal point of concern for oil exporters, as regional instability can threaten shipping routes. Reports indicate that only about half of the loaded vessels managed to safely navigate the Strait in April. Iraq's decision to reduce prices is a tactical response to the fear that buyers may hesitate to undertake the risk of shipping through this narrow yet crucial passage. By shifting some of that risk onto buyers—who now assume ownership at the port after braving the transit—Baghdad is making a conscious effort to secure its oil export market amidst turbulence. The Implications of Dynamic Pricing Strategies While the allure of lower prices may initially seem like a boon for buyers, it signals deeper issues at play within the oil market. As Iraq competes against rivals like Saudi Arabia and the UAE, these aggressive discounts serve not only to attract business but also to reflect the underlying tumult in global energy markets. Analysts suggest that such price strategies may offer short-term gains but could escalate volatility in the price of crude oil if geopolitical tensions do not abate. Future Predictions: Iraq's Oil Market at a Crossroads Looking forward, Iraq's approach presents both opportunities and risks. The market could witness further price fluctuations as the geopolitical climate continues to evolve. In exchange for discounted rates, buyers are effectively betting on both the safety of their shipments and the future stability of Iraq's energy sector. As the situation in the Strait remains precarious, there are fears that any renewed threats could dramatically reverse the current price reductions, burdening the global oil market with additional increases. Iraq’s determination to maintain its oil output through substantial price cuts highlights the vulnerability of oil supply chains and reflects a broader strategy to stay competitive in a challenging environment. Understanding this intricate scenario is crucial for investors and consumers alike, as the repercussions of today's decisions may shape the global energy landscape for years to come. Take Action: Stay Informed on Oil Market Trends To navigate the complexities of the oil market successfully, it’s essential to stay informed about ongoing developments in Iraq and the Strait of Hormuz. Monitoring regional dynamics will provide critical insights for those invested in energy futures, enabling better strategic decisions in this volatile market.

05.09.2026

Unlock the Power of Chest Training: Best Chest Exercises for Women

Update Why Women Shouldn't Neglect Chest Training In the realm of fitness, women are often encouraged to focus on their legs and glutes, while the chest area remains an overlooked territory. However, this could be a misstep, as training the chest brings a multitude of advantages. Firstly, it aids in body composition; as women strive to shed fat, maintaining muscle through chest workouts ensures that more of the weight lost is fat rather than muscle. Secondly, a balanced upper body requires equal attention to all muscle groups to prevent asymmetrical physiques. Lastly, strengthening the chest contributes to overall functional strength, enhancing daily activities—be it lifting groceries or engaging in sports. Dispelling the Myths: Chest Training Will Not Make You Bulky Common misconceptions often inhibit women from pursuing effective chest exercises. A prevalent belief is that training this area will lead to a bulky appearance. Experts clarify that this is not the case; hypertrophy (muscle growth) requires a consistent caloric surplus and a highly focused training regime. For most women, achieving overly muscular pecs simply won't happen without intentional and extensive effort. Instead, strengthening the chest subtly enhances muscle and may create a firmer aesthetic in the breast area due to the musculature beneath. The Best Chest Exercises for Women To strengthen the pectoral region effectively, the integration of compound movements is key. Exercises like bench presses and push-ups engage not only the chest but also the triceps and shoulders, promoting balanced strength. Reference articles emphasize the importance of starting with foundational movements: Push-Ups: Effective for building strength and endurance in the chest and triceps. Bench Press: An excellent tool for targeting the pectoralis major effectively. Dumbbell Flys: These help improve flexibility and increase the stretch and contraction of the chest muscle. Adding Variety: The Importance of Progressive Overload Progressive overload is crucial for muscle development. Gradually increasing the weights or the number of repetitions allows continued adaptation in the muscles. Integrating varied workouts not only prevents monotony but helps in achieving overall upper-body strength. For instance, alternating between heavy bench presses and lighter weight dumbbell flys can be an effective strategy. Functional Benefits: Beyond Aesthetics While the aesthetic appeal of stronger pecs is an enticing benefit, the functional advantages are equally compelling. Improved chest strength supports better posture and can relieve strain in the shoulders and back, significantly reducing injury risk. It also enhances performance in day-to-day activities requiring pushing motions, such as opening heavy doors or completing household chores effortlessly. Incorporating Chest Training into Your Routine Fortunately, adding chest exercises to your weekly routine doesn’t demand excessive time commitment. One dedicated chest workout per week can adequately support strength goals, especially when integrated into a complete upper-body training program. As unique workout routines continue to evolve, platforms are available to optimize your training, many of which, like apps or online coaching, provide tailored guidance based on personal goals. Emotional and Mental Benefits of Chest Training Women often overlook how physical strength translates to mental resilience. Achieving new fitness milestones can significantly boost confidence and body image. In many circumstances, pushing through challenging workouts generates a sense of accomplishment, reinforcing the idea that these goals are attainable. Additionally, creating a community around shared fitness goals can amplify motivation, encouraging participants to stay committed to their routines. Call to Action: Reimagine Your Fitness Journey Today! Redefine your workout ethos, embracing the power of a strong upper body. Don't shy away from chest training, as it carries a wealth of benefits — physically and mentally. Explore diverse chest exercises and consider enlisting a personal trainer to enhance your technique. Surround yourself with a supportive community, as embarking on this fitness journey is more enjoyable when shared!

05.08.2026

Phio Pharmaceuticals Advances PH-762 in Skin Cancer Treatment: Positive Results Emerge

Update Phio Pharmaceuticals Reports Exciting Progress in Cancer Treatment ResearchPhio Pharmaceuticals Corp. (NASDAQ: PHIO) has made significant strides in the development of its lead clinical candidate, PH-762, targeting cutaneous squamous cell carcinoma (cSCC), melanoma, and Merkel cell carcinoma. In a recent update, the company outlined its achievements in the first quarter of 2026 following the completion of their multi-center Phase 1b clinical trial. This localized approach to immunotherapy leverages proprietary INTASYL® gene silencing technology aimed at offering new hope for cancer patients while minimizing harmful side effects typically associated with systemic treatments.PH-762's Clinical Trial Shows PromiseIn March 2026, the results from the Phase 1b clinical trial were presented at the American Academy of Dermatology (AAD) Annual Meeting. The trial involved administering PH-762 through intratumoral injections, targeting the PD-1 pathway to modulate immune responses within the tumor microenvironment. The results were encouraging, with 65% of patients experiencing significant pathological responses. Notably, among those treated, 45% achieved complete pathological response, indicating a serious advancement in efficacy compared to previous therapies.Balancing Efficacy with SafetyOne of the most significant findings from the trial is PH-762's safety profile. Unlike traditional systemic therapies that often cause immune-related adverse events, PH-762 demonstrated no serious adverse events or dose-limiting toxicities. This localized delivery mechanism is designed to focus treatment directly where it’s needed, potentially reducing systemic toxicity. As stated by Dr. Mary Spellman, one of the trial's lead investigators, the approach aims to bring "immune balance to treat tumor cells," suggesting that this could pave the way for safer treatment strategies.Financial Health Supporting Ongoing ResearchPhio Pharmaceuticals has strengthened its financial position through strategic equity financings, securing approximately $23.7 million in net proceeds during 2025. This financial backing allows the company to extend its operational runway into the first half of 2027, supporting continued clinical development of PH-762 and related strategic initiatives.Next Steps and FDA InteractionsLooking ahead, Phio is preparing for an upcoming interface with the FDA that will outline the next steps for advancing PH-762’s development program. The submission is scheduled for the second quarter of 2026 and aims to clarify the design of future studies and ensure that the promising results can translate into effective treatments for cancer patients.Potential Implications for PatientsThe development of PH-762 represents a significant advancement in immunotherapy for skin cancers, addressing the acute need for effective treatments that do not compromise patient safety. With the ongoing evaluation of its efficacy and safety, there is cautious optimism for the drug's potential to transform the landscape of cancer treatment.Final ThoughtsAs Phio Pharmaceuticals navigates this critical phase of development, the biotechnology community will be watching closely. Successful trials could bring a breakthrough not just for those suffering from cutaneous carcinomas, but also inspire further innovations in cancer therapies. Supporters and stakeholders should follow the company's progress as it approaches a pivotal juncture in its roadmap to bringing PH-762 to market.

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*